ArticleDrug design, development and therapy2026
Comparison of Remimazolam and Propofol in Large Skull Base Tumor Resections: Effects on Hemodynamic Stability, Neurocognitive Recovery, and Inflammatory Response.
Article in Drug design, development and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Skull base large tumor resections require precise hemodynamic control and neuroprotection. This study compared remimazolam and propofol effects on perioperative stability, postoperative neurocognitive recovery, and inflammatory responses in these patients. Methods: This retrospective study included patients who underwent large skull base tumor resections between March 2020 and February 2022. Patients were assigned to remimazolam or propofol group based on the primary anesthetic used. Hemodynamic parameters such as blood pressure, heart rate (HR), and mean arterial pressure (MAP) were recorded during the perioperative period. Serum levels of tumor necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6) were measured preoperatively and on postoperative days 1, 3, and 7. Neurocognitive function was assessed using the Montreal Cognitive Assessment (MoCA). Results: The analysis included 257 patients (remimazolam group: n=122; propofol group: n=135). The remimazolam group showed higher systolic blood pressure at most measurement points after induction (immediately before tracheal intubation: 108.24 vs. 105.75, P=0.006), diastolic blood pressure (5 min after extubation: 78.29 vs. 74.87, P=0.005), MAP (immediately before tracheal intubation: 74.83 vs. 70.57, P=0.002), and HR (5 min after extubation: 77.14 vs. 72.93, P=0.002). Postoperative MoCA scores were higher in the remimazolam group (24 hours: 24.18 vs. 23.45, P=0.005). The remimazolam group also had lower levels of postoperative TNF-α (40.21 vs. 41.55, P=0.011) and IL-6 (63.15 vs. 65.19, P=0.013). The incidence of hypotension was lower in the remimazolam group (13.93% vs. 27.41%, P=0.008). Conclusion: For patients with large skull base tumor resections, remimazolam offers better hemodynamic stability, improved early neurocognitive recovery, and milder inflammatory responses compared to propofol.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.